H1 2025 Results Smash Expectations Rezolve AI (NASDAQ: RZLV), a leader in proprietary AI-powered commerce solutions and a strategic partner of Microsoft, Google, and Tether, delivered outstanding financial performance in the first half of 2025. Revenue surged to $6.3 million, exceeding the $5.1 million analyst consensus and representing a 426% year-over-year increase. Gross profit margin…
Company Overview AbCellera is a clinical-stage biotechnology firm focused on discovering and developing antibody-based therapeutics using its proprietary technology platforms. The company collaborates with partners to identify therapeutic antibody candidates and advance internal programs toward clinical development. Volatile Financial Performance AbCellera’s revenue has fluctuated significantly on a quarterly and annual basis. Historical results have not…
Strong Momentum in FY2025 Paves the Way for FY2026 Execution Aeluma, Inc. (NASDAQ:ALMU), a next-generation semiconductor innovator, continued its strategic progression in fiscal year 2025, achieving key milestones across manufacturing, commercialization, and market visibility. The company’s differentiated semiconductor platform is well-positioned to serve high-demand verticals such as artificial intelligence (AI) infrastructure, defense and aerospace, mobile…
Strong Q2 Performance Underscores Business Model Strength GigaCloud Technology (NASDAQ: GCT) reported its highest-ever quarterly revenue, despite operating in a challenging macroeconomic environment. CEO Larry Wu credited this achievement to accelerating performance from the company’s Noble House portfolio, which has now become a meaningful contributor to profit margins. “These results reaffirm the strength of our…
About AbCellera AbCellera is a clinical-stage biotechnology company that leverages advanced technologies to discover and develop antibody-based therapeutics. Founded with the vision of transforming the way antibody drugs are discovered, AbCellera integrates AI-powered drug discovery platforms with deep expertise in immunology and protein engineering. Clinical Development Milestones Achieved AbCellera (Nasdaq: ABCL) announced significant progress in…
